SubsidieMeestersNew generation of bioactive coating for intravenous catheters and implantable medical devices to prevent infections and thrombosis
Developing a novel coating technology using layer-by-layer cross-linked nanogels to prevent thrombosis and bloodstream infections in implantable medical devices, aiming for market readiness.
Projectdetails
Introduction
Catheters and implantable medical devices contacting with the bloodstream are sources of internal blood infections and thrombosis. Catheter-related bloodstream infections are one of the major causes of patient morbidity and mortality in intensive care units.
Impact on Healthcare
Both thrombosis and catheter-related infections lead to prolonged hospital stays, increased risks of mortality, and high costs for the healthcare system. Currently, there is no coating technology on the market that allows for the prevention of these two complications at once.
Innovative Coating Technology
We developed a new innovative coating technology that enables the simultaneous prevention of thrombosis and internal bloodstream infections. This coating is made of layer-by-layer cross-linked nanogels that can be loaded with an antithrombotic and/or antibiotic drug.
Mechanism of Action
We found that the layer-by-layer assembly of these nanogels controls the amount of releasable bioactive agents from coated surfaces. The innovation of our technology is linked to the wider space of used nanoreservoirs that can entrap several bioactive molecules, thus combining several biological activities in a single coating.
Versatility of Application
In addition, these nanoreservoirs can be deposited as a coating on the surface of any biomaterial or medical device, whether metallic, biological, or polymeric.
Consortium and Collaboration
We have built a consortium that combines the key technical and business experience to bring our innovative coating product to market readiness.
Team Composition
- CMD-Coat: A young SME, counts with top researchers and specialists in the field of cardiovascular diseases, biologists, chemists, and pharmacists.
- Fresci: A company specializing in business strategy and innovation management.
Together, we aim to accelerate the technological development and validation of our Coati-X technology and bring to the market a new bioactive coating solution for implantable medical devices.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.476.343 |
| Totale projectbegroting | € 2.476.343 |
Tijdlijn
| Startdatum | 1-4-2024 |
| Einddatum | 31-3-2027 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- CM4CURE SApenvoerder
- SCIENCE&STRATEGY SL
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SAFE-ON Technology for Smart Antimicrobial CoatingsThis project aims to optimize and commercialize the SAFE-ON antimicrobial coating technology through prototype development and market analysis to combat infectious diseases. | ERC POC | € 150.000 | 2022 | Details |
Innovative multifunctional and smart coatings to prevent medical device related infectionsSPARTHA Medical develops multifunctional antimicrobial coatings and eco-friendly sprays to prevent infections in surgical implants and offers customized solutions for various industries. | EIC Accelerator | € 2.389.625 | 2022 | Details |
LipoCoat voor urologie katheters: Terugdringen van urineweg infectiesDit project richt zich op het uitvoeren van een markthaalbaarheidsstudie voor een innovatieve coating op urologiekatheters om infecties te verminderen en kosten te verlagen. | MIT Haalbaarheid | € 20.000 | 2023 | Details |
Antimicrobiële coating voor orthopedische trauma materialenZorgZorg Innovaties Nederland ontwikkelt een antimicrobiële Bioprex-coating voor orthopedische trauma materialen om ziekenhuisinfecties te verminderen en de marktpotentie te vergroten. | MIT Haalbaarheid | € 19.968 | 2022 | Details |
SAFE-ON Technology for Smart Antimicrobial Coatings
This project aims to optimize and commercialize the SAFE-ON antimicrobial coating technology through prototype development and market analysis to combat infectious diseases.
Innovative multifunctional and smart coatings to prevent medical device related infections
SPARTHA Medical develops multifunctional antimicrobial coatings and eco-friendly sprays to prevent infections in surgical implants and offers customized solutions for various industries.
LipoCoat voor urologie katheters: Terugdringen van urineweg infecties
Dit project richt zich op het uitvoeren van een markthaalbaarheidsstudie voor een innovatieve coating op urologiekatheters om infecties te verminderen en kosten te verlagen.
Antimicrobiële coating voor orthopedische trauma materialen
ZorgZorg Innovaties Nederland ontwikkelt een antimicrobiële Bioprex-coating voor orthopedische trauma materialen om ziekenhuisinfecties te verminderen en de marktpotentie te vergroten.